MAPK3 and cancer: As shown in Figure 5A and 5C, either AZD6244, the inhibitor of Erk1/2, or MK2206, the inhibitor of AKT exerts synergistic inhibition of cancer cell growth with metformin respectively, in a dose dependent fashion.